Interpretation of expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples(2024)
-
摘要: 多发性骨髓瘤(multiple myeloma，MM)是血液系统第二大常见恶性肿瘤，标准的整体治疗模式及新药为主的方案极大地改善了MM患者的生存，但微小残留病灶(minimal residual disease，MRD)的存在可导致绝大多数患者的复发。目前，二代流式细胞术(next-generation flow cytometry，NGF)和二代测序(next-generation sequencing，NGS)是基于骨髓样本检测MM患者MRD的主流技术。为了推进MM患者MRD检测技术的标准化和规范化，中华医学会血液学分会实验诊断学组及浆细胞疾病学组、中国医师协会多发性骨髓瘤专业委员会讨论制订了在MM患者中应用NGF和NGS技术进行MRD检测的中国专家共识。为更好地指导临床实践，本文拟对共识的临床和实验室部分进行解读。Abstract: Multiple myeloma(MM) is the second most common hematologic malignant tumor. Standard of care and new drug-based regimens have greatly improved the survival of MM patients, but minimal residual disease(MRD) causes relapse in the vast majority of patients. At present, next-generation flow cytometry(NGF) and next-generation sequencing(NGS) are the mainstream technologies for detecting MRD based on bone marrow samples. To standardize and normalize MRD detection, the Experimental Diagnosis Group and Plasma Cell Disease Group of the Hematology Branch of the Chinese Medical Association, and the Multiple Myeloma Professional Committee of the Chinese Medical Doctor Association discussed and formulated the Chinese expert consensus on the application of NGF and NGS technology for MRD detection in MM patients. To better guide clinical practice, this article intends to interpret the clinical and laboratory parts of the consensus.
-
-
[1] Meseha M, Hoffman J, Kazandjian D, et al. Minimal residual disease-adapted therapy in multiple myeloma: current evidence and opinions[J]. Curr Oncol Rep, 2024 Apr 27. doi: 10.1007/s11912-024-01537-2.Epub ahead of print.
[2] Oliva S, Genuardi E, Belotti A, et al. Multiparameter flow cytometry(MFC)and next generation sequencing(NGS)for minimal residual disease(MRD)evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma(MM)[J]. J Clin Oncol, 2020, 38(15_suppl): 8533. doi: 10.1200/JCO.2020.38.15_suppl.8533
[3] Costa LJ, Chhabra S, Medvedova E, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma(MASTER): final report of the multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2023, 10(11): e890-e901. doi: 10.1016/S2352-3026(23)00236-3
[4] Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma[J]. Blood Adv, 2020, 4(23): 5988-5999. doi: 10.1182/bloodadvances.2020002827
[5] Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis[J]. JAMA Oncol, 2017, 3(1): 28-35. doi: 10.1001/jamaoncol.2016.3160
[6] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials[J]. J Clin Oncol, 2017, 35(25): 2900-2910. doi: 10.1200/JCO.2016.69.2517
[7] Wood B, Jevremovic D, Béné MC, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS-part V-assay performance criteria[J]. Cytometry B Clin Cytom, 2013, 84(5): 315-323. doi: 10.1002/cyto.b.21108
[8] Flores-Montero J, de Tute R, Paiva B, et al. Immunophenotype of normal vs myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma[J]. Cytometry B Clin Cytom, 2016, 90(1): 61-72. doi: 10.1002/cyto.b.21265
[9] Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma[J]. Leukemia, 2017, 31(10): 2094-2103. doi: 10.1038/leu.2017.29
[10] Stetler-Stevenson M, Paiva B, Stoolman L, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition[J]. Cytometry B Clin Cytom, 2016, 90(1): 26-30. doi: 10.1002/cyto.b.21249
[11] Keeney M, Halley JG, Rhoads DD, et al. Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the college of American pathologists flow cytometry proficiency testing program[J]. Arch Pathol Lab Med, 2015, 139(10): 1276-1280. doi: 10.5858/arpa.2014-0543-CP
[12] Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity[J]. Blood, 2013, 122(6): 1088-1089. doi: 10.1182/blood-2013-05-506170
[13] Briney B, Inderbitzin A, Joyce C, et al. Commonality despite exceptional diversity in the baseline human antibody repertoire[J]. Nature, 2019, 566(7744): 393-397. doi: 10.1038/s41586-019-0879-y
[14] Rustad EH, Misund K, Bernard E, et al. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma[J]. Am J Hematol, 2019, 94(12): 1364-1373. doi: 10.1002/ajh.25641
[15] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy[J]. Cancer Cell, 2014, 25(1): 91-101. doi: 10.1016/j.ccr.2013.12.015
[16] Wierda WG, Rawstron A, Cymbalista F, et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations[J]. Leukemia, 2021, 35(11): 3059-3072. doi: 10.1038/s41375-021-01241-1
-
计量
- 文章访问数: 282
- 施引文献: 0
下载: